Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
.png)
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity.
Researchers at Flinders University, Adelaide, Australia, have demonstrated a potential molecular link between COVID-19 and serotonin cells in the gut, suggesting that gut health may have a role to play in driving COVID-19 infection.
The collaborative study investigated gene expression amongst various different cell types lining the gut wall, sequencing and analysing whole genomes from thousands of individuals cells within the intestine. Specialised cells in the gut that synthesised and released serotonin were also discovered to possess a highly enriched expression of a specific SARS-CoV-2 receptor, and were the only type of cells to express all genes associated with COVID-19.
The research may provide further insight into what drives COVID-19 infection and disease severity, potentially supporting previous evidence suggesting antidepressants known as selective serotonin reuptake inhibitors could reduce the severity of COVID-19 symptoms after infection.
Damien Keating, professor and Deputy Director of the Flinders Health and Medical Research Institute and Head of the Gut Sensory Systems research group, commented: “Our study endeavoured to understand whether the gut could be a site of disease transmission and what genes might be associated with the virus entering the cells lining the gut wall.” As the exact site of infection and primary drivers of COVID-19 severity are yet to be fully understood, the researchers behind this study hope to provide important information on the gut’s role in the virus. “Our study adds further evidence that COVID-19 is far more likely to infect cells in the gut and increase serotonin levels through direct effects on the specific gut cells, potentially worsening disease outcomes,” added Keating. “As COVID-19 continues to circulate, further research will be required to advance our understanding of the gut’s role in the virus and continue to find treatment options to work alongside vaccinations.”
The study was published in leading gastrointestinal research journal Gut.
Want to know more about the gut and how it affects overall health? Read our Consumer health trends webinar roundup on the gut microbiome, or watch the webinar itself on-demand.
Source: How the gut may help to drive COVID-19 – News (flinders.edu.au)
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance